BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 01, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Odanacatib: Extension study data

Data from a 2-year extension of a 2-year, double-blind Phase IIb trial showed that 50 mg once-weekly odanacatib for 4 years in 13 evaluable patients increased BMD by 10.7% in the lumbar spine and 8.3% in the hip compared with baseline. Conversely, BMD increases that were achieved with 50 mg odanacatib over the...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >